Option chain shows key data for Portage Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Portage Biotech.

Portage Biotech (NASDAQ:PRTG) Stock, Option Chain

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Biotech

News

Health Care

Movers

Trading Ideas

General

PRTG

Portage Biotech stock jumped after new PORT-7 data showed enhanced immune response and plans advanced for combined A2A and A2B receptor blockade.

Portage Biotech Stock Surges As It Prepares For Human Trial

Nasdaq.Nasdaq100.Nasdaq-100

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

LUCY

MSPR

MULN

Nasdaq Gains Over 50 Points; JPMorgan Posts Upbeat Earnings

Scientist,Pipette,Doppler,Blue,Liquid,In,Test,Tube,Beaker,Laboratory

Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Inc

Press Releases

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Management

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Portage Biotech and Compedica Stock-for-Stock Exchange

LXRX

PRSO

RNAZ

Abpro Hldgs

Ainos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioCardia

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Equillium

Evaxion

Geovax Labs

HCW Biologics

iBio

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Leap Therapeutics

MEI Pharma

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Rallybio

Synlogic

Unity Biotechnology

X4 Pharmaceuticals

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Cantor Fitzgerald

Oppenheimer

Comments

Portage Biotech

Portage Biotech (PRTG) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell